These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 29182383)
1. Ovarian cancer: how can resistance to chemotherapy be tackled? Karakashev S; Aird KM Future Oncol; 2017 Dec; 13(30):2737-2739. PubMed ID: 29182383 [No Abstract] [Full Text] [Related]
2. Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance. Wang X; Li X; Fu X; Bai M; Li X; Mei Q; Nie J; Wu Z; Han W Curr Protein Pept Sci; 2015; 16(4):270-8. PubMed ID: 25929861 [TBL] [Abstract][Full Text] [Related]
3. New drugs for old targets. Salles G Hematol Oncol; 2019 Jun; 37 Suppl 1():101-104. PubMed ID: 31187537 [TBL] [Abstract][Full Text] [Related]
5. Targeted therapy of ovarian cancer including immune check point inhibitor. Kim JY; Cho CH; Song HS Korean J Intern Med; 2017 Sep; 32(5):798-804. PubMed ID: 28823141 [TBL] [Abstract][Full Text] [Related]
6. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748 [TBL] [Abstract][Full Text] [Related]
8. [Chemoresistance in ovarian cancer. State of the art and future prospects]. Katsaros D; Fracchioli S; Arese P; Enria R; Cassinelli P; Mingrone K; Piccinno R; Rigault de la Longrais IA; Massobrio M Minerva Ginecol; 1999 Dec; 51(12):483-99. PubMed ID: 10767997 [TBL] [Abstract][Full Text] [Related]
9. Are targeted agents the key to unlock the code for immune checkpoint inhibitors in soft-tissue sarcomas? Assi T Future Oncol; 2019 Oct; 15(28):3185-3187. PubMed ID: 31578878 [No Abstract] [Full Text] [Related]
10. Metabolic approaches to overcoming chemoresistance in ovarian cancer. Suh DH; Kim MK; No JH; Chung HH; Song YS Ann N Y Acad Sci; 2011 Jul; 1229():53-60. PubMed ID: 21793839 [TBL] [Abstract][Full Text] [Related]
14. The role of membrane transporters in ovarian cancer chemoresistance and prognosis. Cerovska E; Elsnerova K; Vaclavikova R; Soucek P Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):741-753. PubMed ID: 28511565 [TBL] [Abstract][Full Text] [Related]
15. Defective apoptosis underlies chemoresistance in ovarian cancer. Hajra KM; Tan L; Liu JR Adv Exp Med Biol; 2008; 622():197-208. PubMed ID: 18546629 [No Abstract] [Full Text] [Related]
16. Recently identified drug resistance biomarkers in ovarian cancer. Davidson B Expert Rev Mol Diagn; 2016; 16(5):569-78. PubMed ID: 26895188 [TBL] [Abstract][Full Text] [Related]
18. Novel Insights into Membrane Targeting of B Cell Lymphoma. de Winde CM; Elfrink S; van Spriel AB Trends Cancer; 2017 Jun; 3(6):442-453. PubMed ID: 28718418 [TBL] [Abstract][Full Text] [Related]
19. Proteomics of ovarian cancer: functional insights and clinical applications. Elzek MA; Rodland KD Cancer Metastasis Rev; 2015 Mar; 34(1):83-96. PubMed ID: 25736266 [TBL] [Abstract][Full Text] [Related]